Abstract: Therapeutic natural killer (NK) cell-mediated alloreactivity towards acute myeloid leukemia (AML) has largely been attributed to mismatches between killer immunoglobulin-like receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While adult acute B cell precursor leukemia (BCP-ALL) appears to be resistant to NK cell-mediated lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. We here demonstrate in a donor-patient-specific NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate considerable alloreactivity towards pediatric BCP-ALL in vivo. Notably, not only adoptively transferred mature, KIR(+) NK cells but also immature, KIR-NK cells arising early post transplantation in humanized NSG mice (huNSG) exerted substantial anti-leukemic activity. Low-dose and long-term treatment of huNSG mice with the DNA-demethylating agent 5-Aza-cytidine distinctly enhanced the anti-tumor response, interestingly without inducing common inhibitory KIR expression but rather by promoting the differentiation of various NK cell precursor subsets. Collectively, these data indicate that the future design of innovative therapy protocols should consider further exploitation of NK cell-mediated immune-responses for poor prognosis pediatric BCP-ALL patients. 
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INTRODUCTION
Natural killer (NK) cells belong to innate lymphoid immune cells that contribute to anti-tumor responses without prior sensitization. One important receptor family that controls NK cell activity constitutes the HLA class I-restricted killer immunoglobulin-like receptor (KIR) family that comprises both inhibitory and activating family members which recognize allotypic variants of HLA class I alleles as KIR ligands (KIRL). In the setting of haplo-identical hematopoetic stem cell transplantation (HSCT), NK cells maturing in a HLA-disparate recipient will be shaped in the predominantly donor-type-like hematopoietic niche and will thus be donor-tolerant and recipient-"alloreactive", at least during the first months after reconstitution. [1] [2] [3] In this regard, the beneficial effects of promoting a certain degree of donorrecipient HLA-disparity was initially described by the Perugia group that provided evidence that allogeneic HSCTs performed with grafts from KIR-KIRL mismatched donors promoted NK cell alloreactivity and enhanced survival rates in adult patients with acute myeloid leukemia (AML) but not with B cell precursor leukemia (BCP-ALL). For personal use only. on December 9, 2014. by guest www.bloodjournal.org From
MATERIALS AND METHODS

Mice
NOD.Cg-Prkdc
scid IL2rg tmWjl /Sz (NSG) mice were purchased at "The Jackson Laboratory" and maintained under specified pathogen-free conditions in the research animal facility of the University of Tuebingen, Germany. All experimental animal procedures were conducted according to German federal and state regulations.
Induction of leukemia in NSG mice
Patient-specific leukemia was induced in NSG mice as described before. 9 The study was approved by the local ethics committee and written informed consent was obtained from the parents, in accordance with the Declaration of Helsinki. Upon engraftment, mice were sacrificed and bone marrow (BM) or spleen specimens of leukemia-bearing mice were stored at -80° C for de novo generation of patient-specific leukemia at later time points.
NK cell activation and expansion system (NKAES)
Peripheral blood mononuclear cells (PBMCs) from HLA-typed donors (sequence-based typing with 4-digit resolution) (Supplemental Table S1 ) were used with informed consent to expand NK cells in a medium containing 100 IU/ml IL2 (Novartis, Switzerland) using irradiated, membrane bound (mb)IL15-41BBL expressing K562 cells generously provided by D. Campana (University Children's Hospital, Singapore) at a ratio of 1:1.5. 10 To expand NK cells in a GMP-guided fashion, pooled human fresh frozen plasma instead of FCS was used.
Expanded cells were harvested after 14 days and frozen in the presence of 10% DMSO at -80° C. Prior to experiments, NKAES cells were thawed and cultured overnight in the presence of 100 IU/ml IL2 for in vitro cytotoxicity assays or adoptive transfer experiments
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Adoptive NK cell transfer
Donor-patient-pairs were selected that provided a mismatch or match in their KIR-KIRL repertoire (Table 1; Supplemental Tables S1 and S2) . 1 x 10 6 blasts were intravenously injected into unirradiated NSG mice on d0, followed by intravenous injection of 10 x 10 6 NKAES cells at the indicated time points. To monitor engraftment of leukemia, PBMCs of NSG mice were subjected to flow-cytometric analysis using formerly defined patient-specific leukemia surface markers.
Humanization of NSG mice
Humanization of NSG mice was performed as described before. 11 Following approval by the local ethics committee, parents donated < 5% of the hematopoietic stem cells (HSCs) for humanization of NSG mice. In selected experiments, HLA-typed HSCs were purchased from Key Biologics (Memphis, TN, USA). To induce maturation of NK cells, huNSG mice were treated at 12 weeks post transplantation with a complex of IL15/IL15Rα. 12 In addition, huNSG mice were injected once on d15 post initiation of IL15 stimulation by intraperitoneal administration of 100 µg poly I:C (Sigma Aldrich, Taufkirchen, Germany).
13
Determination of in vivo cytotoxicity
Individual donor-patient-pairs were selected that provided a mismatch or a match with respect to their KIR-KIRL repertoire. Mice were transplanted with HSCs of the respective donor and activated as described above at 12-20 weeks post transplantation. To study NK cell-mediated cytotoxicity, 3 x 10 6 blasts were intravenously injected into huNSG and the extent of blasts was determined at 20hrs post injection in the BM using polychromatic (8-11)
For personal use only. on December 9, 2014. by guest www.bloodjournal.org From color flow-cytometry. In some experiments, a mixture of 3 x 10 6 NSG-derived blasts (total 6 x 10 6 blasts) of two patients with varying KIR-KIRL repertoires were injected into huNSG mice and leukemia was quantified using the hierarchical gating strategy depicted in Figure S5A . In all experiments, the frequencies of patient-specific vital blasts were normalized to vital murine CD45 + cells.
In vivo treatment of huNSG mice with 5-Aza-cytidine
On d39 post transplantation, huNSG mice were randomly assigned to treatment or control group and therapy with 5-Aza-cytidine (0.025mg/mouse/dose intraperitoneally, twice a week for a total of 4 weeks) or PBS as control was initiated. 4 weeks later, 3 x 10 6 blasts were intravenously injected into 5-Aza-cytidine or sham-treated animals. 20hrs later, mice were sacrificed and subjected to analysis of NK cell phenotype and for quantification of leukemic burden.
Functional NK cell response staining
Sorted KIR + and KIR -(for the respective sorting KIR mAb cocktail refer to Suppl. Data) NKAES subsets were co-cultured for 6hrs with NALM-16 or K562 cells (E:T ratio of 1:2) in the presence of CD107a-APC (H4A3) (BD Pharmingen). Subsequently, NK cells were stained with the indicated surface antibodies, permeabilized and co-stained with the respective intracellular antibodies (Perforin-PB (dG9) and TNF-bv605 (MAb11)) (Biolegend).
For determination of IFN-γ, unsorted NKAES cells were co-cultured with the respective target cells, were subsequently stained with surface antibodies (including the above mentioned anti-KIR antibody cocktail), and finally stained with IFN-γ-BUV395 (B27) antibody (BD Horizon). Percentages of the respective NK cell subpopulation were then normalized to the baseline levels of NKAES cells cultured in control medium only. The specificity of the intracellular perforin staining was additionally verified by determining the perforin For personal use only. on December 9, 2014. by guest www.bloodjournal.org From concentration in the co-culture supernatants using the Diaclone Perforin ELISA KIT (ACTIVE BIOSCIENCE, Germany).
Alloreactive NK cell subset analysis
Unsorted NKAES cells were co-cultured with the respective target cells in the presence of CD107a-bv421 (H4A3) and subsequently stained with the following mAbs: KIR3DL1 (DX9, BD Pharmingen), KIR2DL2/L3/S2 (GL183, Beckman Coulter), KIR3DL1/S1 (Z27.3.7, Beckman Coulter) and KIR2DL1/S1/S4 (HP-3E4, BD Pharmingen). The selective combination of anti-KIR mAbs with different or identical fluorochromes hereby allowed the discrimination KIR -and non-alloreactive or alloreactive KIR + NK cell subsets in the context of Bw4/C1 target cell recognition. To characterize the alloreactivity of mature NK cells in various KIR-KIRL repertoire constellations, we applied a previously described good manufacturing process (GMP)-guided NK cell activation and expansion system (NKAES) 10 and generated large numbers of cytokine-matured NK cells of donors with defined HLA class I genotypes (Supplemental Table S1 ), KIR repertoires (Supplemental Table S2 ) and NK cell surface phenotypes (Supplemental Figure S1A (Table 1) . In vitro cytotoxicity assays demonstrated that alloreactivity to BCP-ALL was better for those NK cells that were not subject to inhibition by self-HLA molecules ( Figure   1A ). In addition, injection of NKAES cells from a KIR-KIRL mismatched donor into P3B-engrafted NSG mice resulted in a higher reduction of tumor burden than transfer of the respective control NK cells ( Figure 1B , C). (Figure 2A ), a phenomenon that became even more evident upon normalization ( Figure 2B ). In contrast, the KIR + NK cells of matched Figure 5C ). Applying the sequential gating strategy depicted in Figure S5A and verifying that the huNSG-derived NK cells were indeed to a large extent negative for common KIRs ( Figure   5D ), we found that the KIR-KIRL mismatched sample P3B was significantly better killed than the matched sample P23T ( Figure 5E ). Of note, we deliberately euthanized huNSG mice 20hrs post injection of leukemia to exclude for T cell-mediated responses as a major cause of leukemia reduction. As the alloreactivity towards P3B and P23T was reversible in
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For personal use only. on December 9, 2014. by guest www.bloodjournal.org From experiments performed with a different HSC donor ( Figure S5B ), we conclude that the alloreactivity towards P3B depicted in Figure 5E was not a result of a P3B-intrinsic slower growth rate. Given that HLA class I, ICAM-1, NKG2D and DNAM-1 ligands ( Figure S1C) were expressed to a comparable extent by P3B and P23T, we assume that either KIR-KIRL interactions other than the one analyzed by us (KIR2DL1/S1/S4, KIR2DL2/S2/L3 and 3DL1) or modest differences, i.e. in the expression of NKG2DL, must have contributed to this phenomenon. Figure 6D , F). Of note, we had stopped 5-Aza-cytidine therapy three days before the injection of leukemia and the half-life of the drug is described to be less than 4hrs. 21 Together with our data obtained in non-humanized controls ( Figure 6E ), we can therefore largely exclude a drug-induced, direct cytotoxic effect that might have reduced the tumor load.
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NK cell receptor analysis of huNSG mice revealed that 5-Aza-cytidine did not significantly modulate the expression of selected NK cell receptors (KIRs, NKG2A, NKp44 and NKG2D) at the low doses applied ( Figure 7A, B) . However, the analysis of NK cell subsets interestingly showed that 5-Aza-cytidine-treated huNSG mice had clearly higher numbers of As recent data indicate that DNA demethylating agents may not only affect the growth of malignant cells but might also modulate inhibitory KIR expression on NK cells, we tested 5-Aza-cytidine in our huNSG model. Interestingly, we observed a significantly reduced BCP- , we assume that the re-expression of PU.1 might have promoted NK cell differentiation in our model. In addition, it has been shown for low but not high dose 5-Azacytidine therapy that this may increase the number of cells in the S phase and may thus promote cell cycle progression. 38 Recalling data that 5-Aza-cytidine therapy does not evoke a broad and unspecific passive demethylation of the genome but rather induces a highly specific non-random demethylation pattern 38 , we at this point hypothesize that low dose 5-Aza-cytidine might have selectively re-shaped factors important for NK cell transcription and cell cycle control.
In summary, we here provide substantial evidence that both KIR + but also immature KIR -NK cells may exert clinically relevant GvL effects towards pediatric BCP-ALL. Our data thus Uhrberg, PhD, University Clinic of Duesseldorf, Germany for the helpful discussions.
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